Expert Rev Mol Diagn. 2010;10(1):49-64. With the ultimate goal of enabling personalized medicine for PC, massive efforts have been undertaken to identify new and better diagnostic, prognostic and ...

Science is not shy about ambiguity, never more so than when it comes to medical advice. So here’s the latest recommendation on prostate-cancer screening: Men should continue to have both a manual ...

Table 1 Clinico-pathological characteristics and selection criteria for high and normal BMI prostate cancer patients Gene expression features were normalized by using RMAExpress and by ChipInspector ...

Patients with prostate cancer who received androgen deprivation therapy prior to prostatectomy had lower levels of hypoxia inducible factor 1a, and higher expression of VEGF-A and VEGF-C was ...

Survivin is considered as a cancer therapeutic target as aberrant high expression of survivin was documented in many different types of human cancer. 10 It is thought that survivin overexpression ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...

Neuroendocrine prostate cancer (NEPC) after androgen deprivation therapy (ADT): Clinical characteristics. Background: Physical activity (PA), in particular longer duration or higher intensity, may ...

Scientists have identified a genetic signature that appears to reflect the risk of tumor recurrence or spread in men surgically treated for prostate cancer. If confirmed, the finding not only may help ...

A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone therapy to radiation after surgery - the ...

This study was undertaken to investigate the role of mouse double minute 2 (MDM2) oncogene in prostate cancer growth and the potential of MDM2 as a target for prostate cancer therapy. An antisense ...